Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Shockwave therapy shows promise for Parkinson's in tiny trial

NCT ID NCT06676995

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This small study tested a non-invasive device called Transcranial Pulse Stimulation (TPS) in 14 people with Parkinson's disease. TPS uses sound wave pulses to stimulate the brain. Participants received 12 sessions over four weeks. Researchers checked if TPS safely improved movement, thinking, mood, and other symptoms compared to before treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcranial Pulse Stimulation (TPS) device
What this could lead to
If it works, this could point toward a non-invasive way to ease movement, thinking, and mood problems in Parkinson's disease.
What could go wrong
This was a very small, early study with only 14 people and no comparison group. Results may not apply to everyone, and the benefits might be small or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Dec 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of "probable" or "possible" Parkinson's Disease (PD), as defined by the current clinical criteria (52) or as confirmed by a co-investigator neurologist or confirmation via medical records or a letter from a patient's physician. 2. Age from 40 to 90 years old. 3. Disease stages 2 to 4 based on the UPDRS scale subdomain V (or Hoehn and Yahr scale). 4. Taking stable medications for Parkinson's Disease for at least 30 days. Exclusion Criteria: 1. Features suggestive of other causes of parkinsonism/Parkinson's-plus syndromes. 2. History of deep brain stimulation, brain ablation surgeries, or malignant mass brain lesions. 3. History of schizophrenia, bipolar illness, or alcohol/drug abuse within the past six months. 4. Need for rapid clinical response due to conditions such as initiation, psychosis, or suicidality. 5. Contraindications to transcranial brain stimulation (i.e., metal objects in the head, metal implanted brain medical devices, cortisone treatments within six weeks before the first stimulation session, central nervous system (CNS) thrombosis, etc). 6. Unstable medical conditions (e.g., uncontrolled diabetes, uncompensated cardiac issues, heart failure, uncompensated pulmonary disease, or chronic obstructive pulmonary disease). 7. Contraindications to MRI according to Mass General Brigham screening in the Martinos Center (i.e., pacemaker, defibrillator or wires other than sternal wires, metallic foreign body in the eye, or drug infusion devices - if the models of these devices are not compatible with MRI). 8. Pregnancy. 9. Epilepsy or disorders that significantly increase the likelihood of seizures, including: (i) severe traumatic brain injury; (ii) congenital birth defects leading to seizures; (iii) brain tumor; (iv) metabolic disorders associated with seizures; (v) intracranial or subarachnoid hemorrhage; and (vi) non-lacunar strokes. 10. Bed- or wheelchair-bound patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Spaulding Rehabilitation Hospital

    Cambridge, Massachusetts, 02138, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.